Get the Stockscreener App
12.53
3.84%
-0.50
Tonix Pharmaceuticals Holding Corp stock is traded at $12.53, with a volume of 504.87K.
It is down -3.84% in the last 24 hours and up +14.32% over the past month.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
See More
Previous Close:
$13.03
Open:
$13.07
24h Volume:
504.87K
Relative Volume:
1.04
Market Cap:
$199.74M
Revenue:
$13.11M
Net Income/Loss:
$-124.02M
P/E Ratio:
-0.8786
EPS:
-14.261
Net Cash Flow:
$-107.25M
1W Performance:
+1.54%
1M Performance:
+14.32%
6M Performance:
-19.06%
1Y Performance:
-70.42%
1-Day Range:
$12.36
$13.15
1-Week Range:
$12.10
$13.19
52-Week Range:
$10.03
$69.97
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Name
Tonix Pharmaceuticals Holding Corp
Sector
Industry
Phone
212-980-9155
Address
200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY
Compare TNXP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
12.53 | 199.74M | 13.11M | -124.02M | -107.25M | -14.26 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-18-22 | Initiated | Noble Capital Markets | Outperform |
| Apr-18-19 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-18-17 | Upgrade | ROTH Capital | Neutral → Buy |
| Sep-07-16 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-17-16 | Reiterated | Oppenheimer | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-12-15 | Initiated | Oppenheimer | Outperform |
| Feb-17-15 | Reiterated | ROTH Capital | Buy |
| Sep-29-14 | Reiterated | ROTH Capital | Buy |
View All
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia Drug - Stocktwits
Why TNXP Stock Is Suddenly Back On Retail Radar - Stocktwits
Tonix Pharmaceuticals (TNXP) Investor presentation Summary - Quartr
Form 4 Tonix Pharmaceuticals Holding Corp For: 9 July By Investing.com - Investing.com Nigeria
Tonix (NASDAQ: TNXP) CFO adds 1,453 shares through 2025 employee stock plan - Stock Titan
TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff - Stocktwits
Technical Reactions to TNXP Trends in Macro Strategies - Stock Traders Daily
Tonix: 'Hold' Based On Tonmya Payer Expansions And MDD Trial Initiation - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
Tonix Pharmaceuticals Holding Corp. has enrolled the first patient in its Phase 2 “HORIZON” study of TNX-102 SL (sublingual tablet) for the treatment of major depressive disorder (MDD). - Bitget
Tonix: Slow Start For Tonmya, Speculative Pipeline Warrants Hold Rating (NASDAQ:TNXP) - Seeking Alpha
Tonix enrolls first patient in Phase 2 depression study - grafa.com
Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD) - The Manila Times
Tonix Pharma Begins Pivotal Phase 2 Depression Trial - TipRanks
Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for Major Depressive Disorder - Quiver Quantitative
Tonix Pharmaceuticals Announces First Patient Enrolled in - GlobeNewswire
Tonix starts Phase 2 depression trial for TNX-102 SL - Stock Titan
Tonix Pharmaceuticals Holding Corp. Actuals & Estimates (DUS:TPM0) - TradingView
Enterprise value to revenue forward of Tonix Pharmaceuticals Holding Corp. – NASDAQ:TNXP - TradingView
Tonix Pharmaceuticals Holding Corp. Actuals & Estimates (NASDAQ:TNXP) - TradingView
Tonix Pharmaceuticals Holding Corp. Actuals & Estimates (FWB:TPM0) - TradingView
Enterprise value to EBIT forward of Tonix Pharmaceuticals Holding Corp. – NASDAQ:TNXP - TradingView
Price to sales forward of Tonix Pharmaceuticals Holding Corp. – NASDAQ:TNXP - TradingView
Enterprise value to EBITDA forward of Tonix Pharmaceuticals Holding Corp. – NASDAQ:TNXP - TradingView
Tonix Pharmaceuticals (TNXP) Receives Strong Buy Rating with $26 Target - GuruFocus
TNXP Forecast — Price Target — Prediction for 2027 - TradingView
TNXP Initiated Coverage by Raymond James -- Price Target Set at $26 - GuruFocus
Raymond James initiates Tonix Pharma stock coverage with strong buy By Investing.com - Investing.com South Africa
Raymond James initiates Tonix Pharma stock coverage with strong buy - Investing.com
TNXP Stock Rises Premarket: Investors Cheer Early Traction For Fibromyalgia Drug Despite Weak Q4 Print - Stocktwits
Tonix Pharmaceuticals Holding Corp (TNXP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Trading the Move, Not the Narrative: (TNXP) Edition - Stock Traders Daily
Millennium Management LLC Increases Stake in Tonix Pharmaceuticals Holding Corp - GuruFocus
Millennium Management LLC Increases Stake in Tonix Pharmaceutica - GuruFocus
Tonix Pharmaceuticals Holding (TNXP) price target decreased by 15.76% to 55.42 - MSN
Tonix Pharmaceuticals Holding Corp (TNXP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tonix Pharmaceuticals Holding Corp (TNXP) Institutional Confidence - TradingKey
Tonix Pharmaceuticals Holding Corp - TradingKey
Tonix Pharmaceuticals Holding Corp (TNXP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tonix Pharmaceuticals Holding Corp (TNXP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Tonix Pharmaceuticals Holding Corp (TNXP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):